journal article·2019-12-04Open access

DPP-4 inhibitor anagliptin protects against hypoxia-induced cytotoxicity in cardiac H9C2 cells

Yunxiang Ma, Junkai Wang, Changhua Wang, Qiong Zhang, Yannan Xu, Huajin Liu, Xia Xiang, Jiangwei Ma

Abstract

Cardiovascular complications are the leading cause of mortality and morbidity in type 2 diabetes patients. Diabetes greatly increases the risk of heart disease; therefore, the management of diabetes often involves the prevention of heart disease. DPP-4 inhibitors have been proven to be the effective therapeutic agents of glycaemic control. Recent studies have shown that certain types of DPP-4 inhibitors could also have cardiovascular benefits. In this study, we examined the protective role of the newly developed DPP-4 inhibitor anagliptin in cultured cardiac myocytic cell line H9C2 cells. Our data show that exposure of H9C2 cells to hypoxic conditions induced higher expression of DPP-4, indicating that DPP-4 is a hypoxia-inducible factor. The inhibition of DPP-4 by anagliptin ameliorates hypoxia-induced cytotoxicity and induction of the pro-inflammatory cytokines IL-6 and MCP-1. Anagliptin also suppresses hypoxia-induced oxidative stress as revealed by the detected levels of cellular ROS and reduced GSH. Moreover, anagliptin protects myocytes from hypoxia-associated reduced mitochondrial membrane potential. Mechanistically, we show that anagliptin promotes hypoxia-induced NFR2/HO1 induction but suppresses HMGB1 and MyD88 generation. Collectively, our data indicate that anagliptin-mediated DPP-4 inhibition is a protective mechanism in cardiomyocytes and imply that the DDP-4 inhibitor anagliptin plays dual roles by lowering glucose and protecting cardiomyocytes.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Diabetes Treatment and Management · Metabolism, Diabetes, and Cancer · Neuropeptides and Animal Physiology

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Southern Medical University Affiliated Fengxian Hospital

Tengzhou Central People's Hospital

Shanghai University of Medicine & Health Sciences

Funding

Shanghai Science and Technology Commission

References (30)

Show source-provided references
1. 10.2337/diabetes.54.6.161510.2337/diabetes.54.6.1615 ↗
2. 10.2337/diacare.26.2007.S3310.2337/diacare.26.2007.S33 ↗
3. 10.1517/14656566.2013.82496610.1517/14656566.2013.824966 ↗
4. 10.1161/CIRCULATIONAHA.117.02813610.1161/CIRCULATIONAHA.117.028136 ↗
5. 10.1016/j.amjcard.2017.05.01510.1016/j.amjcard.2017.05.015 ↗
6. 10.1080/07853890.2017.133542810.1080/07853890.2017.1335428 ↗
7. 10.1016/j.vph.2018.05.01010.1016/j.vph.2018.05.010 ↗
8. 10.1016/j.bmc.2011.09.04310.1016/j.bmc.2011.09.043 ↗
9. 10.1210/en.2012-185510.1210/en.2012-1855 ↗
10. 10.3892/mmr.2017.766710.3892/mmr.2017.7667 ↗
11. 10.1161/JAHA.116.00477710.1161/JAHA.116.004777 ↗
12. 10.1536/ihj.16-54710.1536/ihj.16-547 ↗
13. 10.2147/DMSO.S5467910.2147/DMSO.S54679 ↗
14. 10.14740/jocmr3464w10.14740/jocmr3464w ↗
15. 10.1007/s10863-018-9746-z10.1007/s10863-018-9746-z ↗
16. 10.1007/s10863-014-9598-010.1007/s10863-014-9598-0 ↗
17. 10.1007/s10863-019-09792-w10.1007/s10863-019-09792-w ↗
18. 10.1172/JCI20052440810.1172/JCI200524408 ↗
19. 10.1016/j.bbamcr.2014.11.01510.1016/j.bbamcr.2014.11.015 ↗
20. 10.1155/2014/26042910.1155/2014/260429 ↗
21. 10.1161/CIRCRESAHA.116.30658810.1161/CIRCRESAHA.116.306588 ↗
22. 10.1007/s00395-014-0450-910.1007/s00395-014-0450-9 ↗
23. 10.1007/s13238-012-2063-010.1007/s13238-012-2063-0 ↗
24. 10.1186/s12872-017-0704-110.1186/s12872-017-0704-1 ↗
25. 10.1016/j.biopha.2018.10.03510.1016/j.biopha.2018.10.035 ↗
26. 10.1016/j.molimm.2019.01.00610.1016/j.molimm.2019.01.006 ↗
27. 10.1016/j.biopha.2018.04.18710.1016/j.biopha.2018.04.187 ↗
28. 10.1016/j.freeradbiomed.2018.04.58010.1016/j.freeradbiomed.2018.04.580 ↗
29. 10.1007/s00125-016-4071-810.1007/s00125-016-4071-8 ↗
30. 10.1007/s10557-018-6776-z10.1007/s10557-018-6776-z ↗